Litigation Details for Novartis Pharmaceuticals Corporation v. Alkem Laboratories Ltd. (D. Del. 2019)
✉ Email this page to a colleague
Novartis Pharmaceuticals Corporation v. Alkem Laboratories Ltd. (D. Del. 2019)
Docket | ⤷ Sign Up | Date Filed | 2019-10-17 |
Court | District Court, D. Delaware | Date Terminated | |
Cause | Assigned To | Leonard Philip Stark | |
Jury Demand | Referred To | ||
Patents | 8,101,659; 8,796,331; 8,877,938; 9,388,134 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in Novartis Pharmaceuticals Corporation v. Alkem Laboratories Ltd.
Details for Novartis Pharmaceuticals Corporation v. Alkem Laboratories Ltd. (D. Del. 2019)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2019-10-17 | 1 | Complaint | expiration of U.S. Patents Nos. 8,101,659 (the “’659 patent”), 8,796,331 (the “’331 patent”), 8,877,938 (… (the “’938 patent”), and/or 9,388,134 (the “’134 patent”). … THE PATENTS-IN-SUIT AND ENTRESTO® 178. Novartis is the owner of the ’659 patent, titled…copy of the ’659 patent is attached hereto as Exhibit A. 179. The ’659 patent claims, inter alia…the ’331 patent, titled “Methods of treatment and pharmaceutical composition.” The ’331 patent was duly | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |